# US 10,946,072 B2 · Method for treating dermatitis and improving skin texture using B-type natriuretic peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,072 B2
- Document ID: US10946072B2
- Status: Granted
- Kind: B2
- Application number: 15/837,964
- Filed: 2017-12-11
- Published: 2018-04-12
- Granted: 2021-03-16
- Earliest claimed: 2009-07-23
- Assignees: IGISU Co., Ltd.
- Applicants: IGISU Co., Ltd.
- Inventors: Kyoko Endo
- Web page: https://patentgrep.com/patent/US10946072B2

## CPC

- A61K 38/2242: {Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/08: Antiseborrheics
- A61P 17/10: Anti-acne agents
- A61P 17/14: for baldness or alopecia
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/10: Antimycotics
- A61P 31/22: for herpes viruses
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 1/02: Preparations containing skin colorants, e.g. pigments (preparations in powder form A61Q1/12)
- A61Q 17/04: Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/10: Washing or bathing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The problem to be solved by the present invention is to provide a safe and efficacious therapeutic agent for dermatitis which is not only safe and efficacious for patients with dermatitis, in particular atopic dermatitis, but also significantly effective for severe cases that are judged to be intractable by conventional external preparations, and which is also safely applicable to affected areas such as the face and neck, as well as to subjects with sensitive skin, such as infants and females. Furthermore, the invention aims to provide an external preparation that is efficacious as skin care cosmetics having effects to improve elasticity and wrinkles of the skin, moisturizing effects, and hair-growth effects. The means for solving the problem is a skin external-preparation composition, in particular, a therapeutic agent for dermatitis or a skin texture-improving agent, having C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.

## Claims

### Claim 1

A method for treating dermatitis, comprising: externally applying a composition comprising an effective amount of a B-type natriuretic peptide (BNP) derivative to skin of a subject in need of such treatment, wherein:
said BNP derivative comprises a peptide having an amino acid substitution between the 10th cysteine and the 26th cysteine residues that are bonded by a disulfide bond to form a ring structure in a BNP selected from BNP-26, BNP-32 and BNP-45, and said BNP derivative has BNP activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the BNP is BNP-26.

### Claim 3 (depends on 1)

The method of claim 1, wherein the BNP is BNP-32.

### Claim 4 (depends on 1)

The method of claim 1, wherein the BNP is BNP-45.

### Claim 5 (depends on 1)

The method for treating dermatitis according to claim 1, wherein the dermatitis is selected from the group consisting of atopic dermatitis, dermatitis that led up to steroid dermatitis, steroid resistant dermatitis, dermatitis to which tacrolimus is not applicable, chronic dermatitis, erythroderma, eczema, contact dermatitis, seborrheic dermatitis, autosensitization dermatitis, stasis dermatitis, urticaria, drug eruption, dermal vasculitis, prurigo, pruritus cutaneus erythema, psoriasis, rosacea, rosacea like dermatitis, lichen planus, and follicular keratosis.

### Claim 6 (depends on 1)

The method for treating dermatitis according to claim 1, wherein the dermatitis is an inflammation associated with at least one rash symptom selected from the group consisting of erythema, infiltrative erythema, lichenified lesion, scales, adhesion of crusts, eczema, abrasion, excoriation, prurigo nodularis, papule, erosions, infiltration, vesicle, and edema.

### Claim 7 (depends on 1)

The method for treating dermatitis according to claim 1, wherein the dermatitis shows an immune reaction to at least one allergen selected from the group consisting of house dust, mites, cedar pollen, orchard grass pollen, ragweed pollen, egg white, and egg yolk.

### Claim 8 (depends on 1)

The method for treating dermatitis according to claim 1, wherein the dermatitis occurs in at least one region selected from the group consisting of face, neck, back, and arms.

### Claim 9 (depends on 1)

The method for treating dermatitis according to claim 1, wherein the dosage form of the composition is selected from the group consisting of ointment, gel, cream, lotion, solution, spray, and patch.

### Claim 10

A method for improving skin texture, comprising: externally applying a composition comprising an effective amount of a B-type natriuretic peptide (BNP) derivative to skin of a subject in need of such treatment, wherein:
said BNP derivative comprises a peptide having an amino acid substitution between the 10th cysteine and the 26th cysteine residues that are bonded by a disulfide bond to form a ring structure in a BNP selected from BNP-26, BNP-32 and BNP-45, and said BNP derivative has BNP activity.

### Claim 11 (depends on 10)

The method of claim 10, wherein the BNP is BNP-26.

### Claim 12 (depends on 10)

The method of claim 10, wherein the BNP is BNP-32.

### Claim 13 (depends on 10)

The method of claim 10, wherein the BNP is BNP-45.

### Claim 14 (depends on 10)

The method for improving skin texture according to claim 10, wherein improving skin texture is improving dry skin, rough skin, sensitive skin or fine wrinkles.

### Claim 15 (depends on 10)

The method for improving skin texture according to claim 10, wherein the composition is a skin care product or a quasi drug.

### Claim 16 (depends on 10)

The method for improving skin texture according to claim 10, wherein the dosage form of the composition is cream, foam, skin lotion, facial mask, skin-softening water, skin emulsion, foundation, makeup base, essence, soap, liquid cleanser, bath agent, sun-block cream, suntan oil or spray type liquid preparation.

### Claim 17 (depends on 1)

The method of claim 1, wherein a concentration of the BNP derivative in the composition is 1-500 μg/g.

### Claim 18 (depends on 10)

The method for improving skin texture according to claim 10, wherein a concentration of the BNP derivative in the composition is 1-500 μg/g.